Format

Send to

Choose Destination
Proteomics. 2018 Oct 24:e1700448. doi: 10.1002/pmic.201700448. [Epub ahead of print]

Discovery and Validation of Clinical Biomarkers of Cancer: a Review Combining Metabolomics and Proteomics.

Author information

1
Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, 3052, Australia.

Abstract

Early detection and diagnosis of cancer can allow timely medical intervention, which greatly improves chances of survival and enhances quality of life. Biomarkers play an important role in assisting clinicians and health care providers in cancer diagnosis and treatment follow-up. In spite of years of research and the discovery of thousands of candidate cancer biomarkers, only a few have transitioned to routine usage in the clinic. This review highlights advances in proteomics technologies which have enabled high rates of discovery of candidate cancer biomarkers and evaluates integration with other omics technologies to improve their progress through to validation and clinical translation. Furthermore, it gauges the role of metabolomics technology in cancer biomarker research and assesses it as a complementary tool in aiding cancer biomarker discovery and validation. This article is protected by copyright. All rights reserved.

KEYWORDS:

biomarker; cancer; diagnosis; metabolomics; proteomics

PMID:
30353665
DOI:
10.1002/pmic.201700448

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center